

Gamma Delta T Cell Cancer Therapy Market Size Worth \$4.17 Billion by 2029 - Exclusive Report by TBRC

*The Business Research Company's
Gamma Delta T Cell Cancer Therapy
Global Market Report 2025 – Market Size,
Trends, And Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED
KINGDOM, September 11, 2025
/EINPresswire.com/ -- How Much Is The
[Gamma Delta T Cell Cancer Therapy
Market Worth?](#)

The Business
Research Company

The Business Research Company

In recent times, there has been a fast-paced increase in the size of the gamma delta T cell cancer therapy market. This market is set to rise from \$1.77 billion in 2024 to \$2.11 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 18.9%. The surge during the former period

can be credited to the escalating prevalence of cancer, enhanced consciousness about cell-oriented treatments, enlargement of immuno-oncology investigations, an upturn in clinical trial proceedings in immunotherapy, and rising demand for safer and effective immunotherapies.

The market size for gamma delta T cell cancer therapy is predicted to experience substantial growth in the coming years, expanding to \$4.17 billion in 2029 at a compound annual growth rate (CAGR) of 18.6%. The advancement over the projection period can be credited to the escalating

demand for personalized cancer treatments, intensified focus on reducing instances of graft-versus-host disease, wider acceptance of ready-made cell therapy products, a growing pipeline of therapies reliant on gamma delta T cells, and increased application of gamma delta T cells in solid tumors. Predominant trends throughout this period include the progression of combined immunotherapies, the advancement of cryopreservation methods, the incorporation of artificial intelligence into therapy creation, the use of multi-omics in tumor targeting, and inventive strides in modulating the tumor microenvironment.

“

Get 30% Off All Global
Market Reports With Code
ONLINE30 – Stay Ahead Of
Trade Shifts,
Macroeconomic Trends, And
Industry Disruptors”

*The Business Research
Company*

Download a free sample of the gamma delta t cell cancer therapy market report:
<https://www.thebusinessresearchcompany.com/sample.aspx?id=27290&type=smp>

What Are The Factors Driving [The Gamma Delta T Cell Cancer Therapy Market?](#)

The gamma delta T cell cancer therapy market is poised to expand, propelled by the rising number of clinical trials. Clinical trials are organized research studies in human subjects intended to assess the safety, efficiency, and possible side effects of medical treatments, medications, or interventions. There is a surge in the number of clinical trials due to an increased demand for new therapies targeted at fulfilling unmet medical requirements and enhancing patient outcomes. Clinical trials propel the progress of gamma delta T cell cancer therapy by affirming safety and effectiveness, expediting regulatory authorizations, and facilitating refined treatment protocols. They enhance therapeutic results by delivering essential data that fosters innovation and broader clinical adoption. For example, a report by the Association of the British Pharmaceutical Industry (ABPI), a UK-based non-profit organization, stated that the total annual initiation of industry-supported clinical trials in the UK saw a minor increase of 4.3% in November 2023, going up from 394 in 2021 to 411 in 2022. Hence, the escalating number of clinical trials is spurring the expansion of the gamma delta T cell cancer therapy market.

Who Are The Major Players In The Gamma Delta T Cell Cancer Therapy Market?

Major players in the Gamma Delta T Cell Cancer Therapy Global Market Report 2025 include:

- Novartis AG
- Takeda Pharmaceutical Company Ltd.
- Legend Biotech Corporation
- Immunocore Holdings plc
- Immatics N.V.
- IN8bio Inc.
- American Gene Technologies International Inc.
- Adicet Bio Inc.
- LAVA Therapeutics N.V.
- Acepodia Inc.

What Are The Key Trends Shaping The Gamma Delta T Cell Cancer Therapy Industry?

Leading companies in the gamma delta T cell cancer therapy market are striving to produce innovative solutions like gamma delta ($\gamma\delta$) T cell engager (TCE) platforms. These platforms are engineered to increase effectiveness, enhance targeting, and lower off-tumor toxicity. They work by redirecting and activating $\gamma\delta$ T cells to specifically recognize and eliminate cancer cells, by linking them to tumor-associated antigens. For example, in March 2025, IN8bio Inc., a U.S. biotech firm, introduced the INB 600, their next-gen $\gamma\delta$ TCE platform. This platform is not just designed to target cancer but also autoimmune illnesses. The front runner of this platform, INB 619, specifically zeroes in on CD19 and has proven the ability to amplify $\gamma\delta$ T cells up to 450 times in preclinical trials, resulting in substantial B-cell depletion. The platform leverages the unique attributes of gamma delta T cells, which inherently target malicious cells, and enhances their tumor-fighting ability through engineered engagers. It's designed to counter the

shortcomings of traditional immunotherapies by enhancing specificity, reducing systemic adverse effects, and broadening the spectrum of cancers that can be treated.

Which Segment Accounted For The Largest Gamma Delta T Cell Cancer Therapy Market Share?
The gamma delta t cell cancer therapy market covered in this report is segmented

- 1) By Therapy Type: Adoptive Cell Therapy, Cytokine Therapy, Monoclonal Antibodies, Combination Therapies
- 2) By Cancer Type: Leukemia, Lymphoma, Solid Tumors, Certain Rare Cancers
- 3) By Stage Of Cancer: Early Stage, Advanced Stage, Relapsed Or Refractory
- 4) By Mechanism Of Action: Activation Of T Cells, Inhibition Of Tumor Microenvironment, Targeting Tumor Antigens, Enhancing Immune Checkpoint Inhibition
- 5) By End User: Hospitals, Specialized Clinics, Research Institutions, Pharmaceutical Companies

Subsegments:

- 1) By Adoptive Cell Therapy: Alpha Beta T Cell Therapy, Natural Killer Cell Therapy, Tumor Infiltrating Lymphocyte Therapy, Chimeric Antigen Receptor T Cell Therapy
- 2) By Cytokine Therapy: Interleukin Based Therapy, Interferon Based Therapy, Tumor Necrosis Factor Therapy, Colony Stimulating Factor Therapy, Transforming Growth Factor Therapy
- 3) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
- 4) By Combination Therapies: Monoclonal Antibodies And Cytokines Combination, Checkpoint Inhibitors And Cell Therapy Combination, Chemotherapy And Immunotherapy Combination, Radiation Therapy And Immunotherapy Combination, Vaccine And Immunomodulator Combination

View the full gamma delta t cell cancer therapy market report:

<https://www.thebusinessresearchcompany.com/report/gamma-delta-t-cell-cancer-therapy-global-market-report>

What Are The Regional Trends In The Gamma Delta T Cell Cancer Therapy Market?

In the 2025 Gamma Delta T Cell Cancer Therapy Global Market Report, North America held the leading position in 2024. It is anticipated that Asia-Pacific will witness the most rapid growth within the forecast period. The report encompasses several regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Gamma Delta T Cell Cancer Therapy Market 2025, By [The Business Research Company](#)

Mineral Wool Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/mineral-wool-global-market-report>

Thermal Insulation Material Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/thermal-insulation-material-global-market-report>

Insulation Products Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/insulation-products-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

This press release can be viewed online at: <https://www.einpresswire.com/article/847690795>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.